Skip to Content
Merck
  • In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.

In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.

Antimicrobial agents and chemotherapy (2011-02-24)
Aurélie Pascual, Maud Henry, Sébastien Briolant, Serge Charras, Eric Baret, Rémy Amalvict, Emilie Huyghues des Etages, Michel Feraud, Christophe Rogier, Bruno Pradines
ABSTRACT

The geometric mean 50% inhibitory concentration (IC50) for Proveblue, a methylene blue complying with the European Pharmacopoeia, was more active on 23 P. falciparum strains than chloroquine, quinine, mefloquine, monodesethylamodiaquine, and lumefantrine. We did not find significant associations between the Proveblue IC50 and polymorphisms in the pfcrt, pfmdr1, pfmdr2, pfmrp, and pfnhe-1 genes or the copy numbers of the pfmdr1 and pfmdr2 genes, all of which are involved in antimalarial resistance.

MATERIALS
Product Number
Brand
Product Description

Supelco
N-Desethylamodiaquine dihydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®